1. Specific recommendations for prevention strategies often depend on the ischemic
stroke/transient ischemic attack subtype. Therefore, new in this guideline is a section …

Stroke is a leading cause of permanent disability. Therefore, primary prevention of first
stroke and secondary prevention of recurrent stroke are a high priority. Primary prevention of …

Importance Patent foramen ovale (PFO)–associated strokes comprise approximately 10% of
ischemic strokes in adults aged 18 to 60 years. While device closure decreases stroke …

Background Patent foramen ovale (PFO) is a vestigial congenital cardiovascular structure
present in around 25% of adults. In most cases, PFO is entirely benign and requires no …

We aimed to provide practical recommendations for the screening of subclinical atrial
fibrillation (AF) in patients with ischaemic stroke or transient ischaemic attack (TIA) of …

Importance Recent epidemiologic and therapeutic advances have transformed
understanding of the role of and therapeutic approach to patent foramen ovale (PFO) in …

Introduction: Percutaneous closure of patent foramen ovale (PFO) in selected patients with
cryptogenic cerebrovascular ischemic events (CEs) decreases the risk of recurrent stroke; …

Patent foramen ovale (PFO) is implicated in the pathogenesis of a number of medical
conditions but to date only one official position paper related to left circulation …

Contemporary evidence supports device-based transcatheter interventions for the
management of patients with structural heart disease. These procedures, which include …

Aims Transcatheter closure of patent foramen ovale (PFO) is the recommended stroke
prevention treatment in patients≤ 60 years with cryptogenic ischemic stroke and PFO. Atrial …